Literature DB >> 1325696

Analysis of the amino terminal presequence of the feline immunodeficiency virus glycoprotein: effect of deletions on the intracellular transport of gp95.

E B Stephens1, E J Butfiloski, E Monck.   

Abstract

The envelope glycoprotein of feline immunodeficiency virus (FIV) consists of two noncovalently associated subunits, the surface glycoprotein (SU; gp95) and the transmembrane glycoprotein (TM; gp40). An unusual feature of the open reading frame (ORF) encoding the FIV glycoprotein is the presence of an unusually long amino terminal sequence (149 amino acids, "L" region or n-region of the signal sequence) preceding the predicted hydrophobic signal sequence. To examine the role of this n-region in the biosynthesis of gp95, the gene-encoding signal sequence and the surface glycoprotein (gp95) were expressed using recombinant vaccinia viruses. Glycoprotein mutants were constructed with 25, 42, 73, 102, and 147 amino acids removed from the n-region. Expression studies revealed that deletion of 25-102 amino acids did not appreciably effect the biosynthesis, intracellular transport, and release of gp95 from the cell surface. In contrast, removal of 147 of 149 amino acids resulted in the gp95 that was blocked in release from the cell. These results indicate that between 3 and 47 amino acids of the n-region are required for the proper biosynthesis, processing, and release of the FIV gp95 from infected cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325696     DOI: 10.1016/0042-6822(92)90894-u

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.

Authors:  J Norman Flynn; Mauro Pistello; Patrizia Isola; Lucia Zaccaro; Barbara Del Santo; Enrica Ricci; Donatella Matteucci; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

4.  A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity.

Authors:  D Lindemann; T Pietschmann; M Picard-Maureau; A Berg; M Heinkelein; J Thurow; P Knaus; H Zentgraf; A Rethwilm
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction.

Authors:  J A Beatty; B J Willett; E A Gault; O Jarrett
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.